AMGN Stock Movement Summary Amgen's stock rallied following its Q4 2025 earnings announcement. The company reported fourth-quarter results that beat Wall Street estimates, driven by a 7% increase in drug sales and a lower tax rate. Full-year 2025 showed 10% sales growth and $8.1 billion in free cash flow. Key products demonstrated strong performance, with Repatha, Evenity, and Tespire each achieving over 30% sales growth. The company reported double-digit revenue and earnings growth across multiple franchises including cardiovascular, bone health, oncology, and rare diseases. Amgen provided upbeat 2026 guidance, which analysts cited as a primary driver of the stock's positive movement. TD Cowen raised its price target to $420 from $389, maintaining a Buy rating. The company highlighted 14 blockbuster drugs and pipeline advancements, particularly Meritide for obesity and diabetes treatment.
Read full analysisAMGN Stock Movement Summary Amgen's stock rallied following its Q4 2025 earnings announcement. The company reported fourth-quarter results that beat Wall Street estimates, driven by a 7% increase in drug sales and a lower tax rate. Full-year 2025 showed 10% sales growth and $8.1 billion in free cash flow. Key products demonstrated strong performance, with Repatha, Evenity, and Tespire each achieving over 30% sales growth. The company reported double-digit revenue and earnings growth across multiple franchises including cardiovascular, bone health, oncology, and rare diseases. Amgen provided upbeat 2026 guidance, which analysts cited as a primary driver of the stock's positive movement. TD Cowen raised its price target to $420 from $389, maintaining a Buy rating. The company highlighted 14 blockbuster drugs and pipeline advancements, particularly Meritide for obesity and diabetes treatment.
Amgen Inc (AMGN) is a publicly traded company in the Healthcare sector.